GLP-1s and Vision Loss - How Worried Should You Be? w/ Dr. Luke Sorrell

Show notes

Send us Fan Mail If you're taking a GLP-1, headlines about sudden vision loss can leave you wondering whether the medication helping you lose weight is putting your eyesight at risk. Ana Reisdorf talks with Dr. Luke Sorrell about NAION, a rare optic nerve condition, and the semaglutide research behind those headlines. You'll learn how to put "double the risk" into perspective, what questions to bring to your doctor, and why your health history matters to the conversation. **IN THIS EPISODE** - What NAION is and how it can affect vision - What semaglutide studies suggest, and the limits of observational research - Why relative risk and absolute risk tell different parts of the story - How diabetes, sleep apnea, cardiovascular health, and optic nerve anatomy fit into the discussion - Blood pressure changes, dehydration, and rapid blood sugar changes as possible contributing factors - Questions to ask your prescriber and eye care professional about your individual risk - What remains uncertain about tirzepatide and other GLP-1 medications - Weighing potential eye risks alongside the benefits of GLP-1 treatment **ABOUT THE GUEST** Dr. Luke Sorrell is a board-certified internal medicine physician, Fellow of the American College of Physicians, and founder of Sorrell MD, a concierge longevity and precision telemedicine practice based in Dallas-Fort Worth, Texas, serving patients across the U.S. He trained at UT Houston McGovern Medical School and completed his residency at Baylor University Medical Center in Dallas. His career has spanned hospital medicine, primary care, and longevity medicine. Today, he works with high-performing and health-conscious individuals across the country, using tools like cardiac CT angiography, VO2 max and metabolic testing, DEXA, genomics, and advanced hormone and lipid panels to identify health risks earlier. He also advises health tech companies building the next generation of care. **CONNECT WITH DR. LUKE SORRELL** Website: https://www.sorrell-md.com LinkedIn: https://www.linkedin.com/in/luke-sorrell-md/ Instagram: https://www.instagram.com/sorrellmd/ Facebook: https://www.facebook.com/SorrellMD Substack: https://substack.com/@sorrellmd **SPONSOR** Tyde Wellness offers GLP-1 care with licensed providers, nutrition guidance, and ongoing support. Use code GLP1Hub50 for $50 off your first month. https://tydewellness.com/GLP1Hub **CHAPTERS** 00:00 GLP-1s and NAION: The "double risk" headline 01:42 Meet Dr. Luke Sorrell 02:52 What is NAION? 05:10 How rare is NAION? 06:13 Diabetes, sleep apnea, and other risk factors 07:50 What the studies show and their limitations 10:49 Relative risk versus absolute risk 11:58 Sponsor: Tyde Wellness 13:22 Semaglutide, tirzepatide, and unanswered questions 14:22 Possible mechanisms: Blood pressure, oxygen, and hydration 19:05 Eye exams, optic nerve anatomy, and rapid A1C changes 22:15 Questions to bring to your doctor 24:54 Ana's Plateau Breakthrough Playbook 26:15 Staying grounded when health headlines spread 27:20 Retatrutide and the future of GLP-1 treatment 29:31 Connect with Dr. Sorrell 30:01 Weighing eye concerns against cardiovascular benefits 31:25 Closing thoughts and podcast reviews MORE FROM GLP-1 HUB 📬 Get The Steady State, Ana's weekly newsletter with GLP-1 guidance from a dietitian who's on one: http://join.glp-1hub.com 🎙 Subscribe wherever you listen to podcasts, and if this episode helped, leave a quick review on Apple Podcasts or Spotify - it's the single best way to help more people find the show. 🌐 Shop GLP-1 essentials, meal plans, and recipes: https://shop.glp-1hub.com 📷 Follow on Instagram: @glp1hub 📺 Watch on YouTube: https://www.youtube.com/@GLP-1hub *Some of the links shared are affiliate links. When you make a purchase, I will receive a small commission at no cost to you. Thank you for supporting the show. *The content of this show is for informational purposes only and does not constitute medical advice. The goal of this show is to provide various points of view about GLP-1 Medications. The personal and professional opinion of the guests and their content does not necessarily reflect the opinion of Ana Reisdorf or GLP-1 Hub.